Dyne Therapeutics Gets FDA Priority Review for Exon-51 DMD Therapy, PDUFA Date Set for January 21, 2027

Dyne Therapeutics landed a concrete regulatory milestone on July 20, 2026: the FDA accepted its Biologics License Application for zeleciment rostudirsen — also designated DYNE-251, or z-rostudirsen — for Duchenne muscular dystrophy amenable to exon 51 skipping, and granted the filing Priority Review. The PDUFA target action date is January 21, 2027.

The BLA is built on data from the registrational expansion cohort of the global Phase 1/2 DELIVER clinical trial, which met its primary endpoint. The regulatory path is Accelerated Approval, meaning the FDA is relying on dystrophin as a surrogate endpoint rather than waiting for direct functional outcome data — a mechanism Congress created specifically for serious conditions with unmet need.

Dyne is guiding for a potential U.S. commercial launch of z-rostudirsen in Q1 2027, contingent on approval arriving on the anticipated timeline, per the company's July 20, 2026 news release on Globe Newswire.

"This milestone represents significant progress toward our goal of delivering functional improvement for those living with DMD amenable to exon 51 skipping," said John Cox, president and chief executive officer, in the company's July 20, 2026 news release on Globe Newswire.

The balance sheet behind this bet is substantial for a clinical-stage company with zero revenue. Per TipRanks, Dyne held $683.92 million in cash and marketable securities against $22.26 million in debt as of recent reporting, for a net cash position of $661.66 million. That runway is supplemented by a debt facility of up to $400 million with Hercules Capital, Inc., expanded on June 17, 2026. With 165.31 million shares outstanding per Morningstar, the company is not scrambling to fund the path to launch.

The stock closed at $23.45 on July 20, 2026, down $0.29 or 1.22% on the session, per Morningstar — against a 52-week range of $8.25 to $25.00. Volume on July 20 came in at 18,627,269 shares, per Motley Fool's reporting from that session.

The exon-skipping DMD field is not empty. Dyne's BLA submission announcement from May 2026 stated that the company sees "a significant unmet need in DMD for treatments with compelling efficacy, a favorable safety profile and improved dosing convenience" — the company's stated rationale, per that release, for entering a market that already has approved exon-skipping drugs.

Beyond z-rostudirsen, Dyne is advancing four additional development candidates against other DMD exon targets: DYNE-253 targets exon 53 skipping, DYNE-245 targets exon 45, DYNE-244 targets exon 44, and DYNE-255 targets exon 55, per the July 20 release. The breadth of that pipeline means the January 2027 PDUFA decision carries weight beyond the exon-51 population alone.

The PDUFA target action date is January 21, 2027, per the FDA's acceptance. Dyne is simultaneously targeting a Q1 2027 launch preparation timeline, per the July 20 release. Any advisory committee meeting, additional data requests, or labeling discussions between now and that date will be the material events to watch. The company has not disclosed whether an AdCom has been scheduled.

For a clinical-stage company with no revenue, $661.66 million in net cash, a Priority Review designation, and a fixed PDUFA date of January 21, 2027, the FDA's BLA acceptance marks the transition from trial data to regulatory decision calendar.